Trial Profile
An Open-label, Single Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]-Labelled AMG 706 (Motesanib) Followed by Extended Treatment With Motesanib in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Jun 2012
Price :
$35
*
At a glance
- Drugs Motesanib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Amgen
- 05 Jul 2011 New trial record